A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 510
- Population
- ALL · 50 Years
- Duration
- 2010-06-01 to 2012-10-01
- Intervention
- pazopanib eye drops; placebo; ranibizumab intravitreal injection
- Comparator
- placebo control arm; active open-label control arm
- Outcomes measured
- Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Trea…; Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks — Up to 52 weeks; Number of Participants With BCVA Over Time — Up to Week 52; Number of Participants Analyzed for Visual Acuity (VA) Response Over Time — Week 52; Change From Baseline in Center Point Thickness (CPT) Over Time — Baseline and Week 52; Number of Participants That Met Criteria for Re-injection — Up to Week 52; Change From Baseline in the Area of Choroidal Neovascularisation (CNV) — Day 1, Week 28 and Week 52; Change From Baseline in the Area of the CNV Lesion Complex (i.e. CNV, Blood, PED, and Fibrosis) — Day 1, Week 28 and We…; Change From Baseline in the Area of Fluorescein Leakage — Day 1, Week 28 and Week 52; Change in Area of Serous Sensory Retinal Detachment (SSRD) — Day 1, Week 28 and Week 52; Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — Up to 52 Weeks; Summary of Potentially Clinically Important Findings for Ophthalmic Examinations — Up to Week 52; Summary of Intraocular Pressure Exam Findings — Up to week 52; Number of Participants With Vital Sign Values Outside of Clinical Concern Range — Up to Week 52; Summary of Abnormal Electrocardiogram (ECG) Findings — Week 4, Week 28, Week 44 and Week 52; Summary of Hematology and Clinical Chemistry Parameters Data of Clinical Concern — Up to Week 52; Number of Participants With Laboratory Data of Clinical Concern for Urine Protein — Day 1 to Week 28 and Week 52; Plasma Concentrations of Pazopanib — Week 4, Week 24 and Week 52
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.